{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:01:02Z","timestamp":1790402462355,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Current treatment guidelines for arrhythmogenic right ventricular cardiomyopathy (ARVC) mainly emphasize on prevention of ventricular arrhythmic events. Despite the progressive nature of ARVC, therapeutic options focusing on decelerating disease progression are scarce.<\/jats:p><jats:p><jats:bold>Methods and Results:<\/jats:bold> This retrospective observational cohort study included 311 patients [age, 39.1 \u00b1 14.4 years; male, 233 (74.9%)] with a definite diagnosis of ARVC as determined by the 2010 Task Force Diagnostic Criteria. Among them, 113 patients (36.3%) received ACEI\/ARB treatment. Disease progression was evaluated according to repeat transthoracic echocardiograms with a linear mixed model. Patients receiving ACEI\/ARB treatment were associated with slower disease progression reflected by a gradual decrease in tricuspid annular plane systolic excursion than those not receiving ACEI\/ARB treatment (0.37 vs. 0.61 mm per year decrease, <jats:italic>P<\/jats:italic> &amp;lt; 0.001) and slower dilation of right ventricular outflow tract (0.57 vs. 1.06 mm per year increased, <jats:italic>P<\/jats:italic> = 0.003). Cox proportional hazard regression models were used to evaluate the association between life-threatening ventricular tachycardia events and ACEI\/ARB treatment. A reduced risk of life-threatening ventricular arrhythmia was associated with ACEI\/ARB treatment compared to that without ACEI\/ARB treatment (adjusted HR: 0.71, 95% CI: 0.52\u20130.96, <jats:italic>P<\/jats:italic> = 0.031).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> ACEI\/ARB treatment is associated with slower disease progression and lower risk of life-threatening ventricular arrhythmia in patients with ARVC. Delaying disease progression may pave way for reducing life-threatening ventricular arrhythmia risk.<\/jats:p>","DOI":"10.3389\/fcvm.2021.769138","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T04:53:27Z","timestamp":1636692807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy"],"prefix":"10.3389","volume":"8","author":[{"given":"Bin","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingmin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801213180301","article-title":"Right ventricular cardiomyopathy and sudden death in young people","author":"Thiene","year":"1988","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037230","article-title":"Sudden death and left ventricular involvement in arrhythmogenic cardiomyopathy","author":"Miles","year":"2019","journal-title":"Circulation."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22648","article-title":"Long-term follow-up of arrhythmogenic right ventricular cardiomyopathy patients with an implantable cardioverter-defibrillator for prevention of sudden cardiac death","author":"Yin","year":"2017","journal-title":"Clin Cardiol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-015-6583-8","article-title":"Pharmacotherapy and other therapeutic modalities for managing arrhythmogenic right ventricular cardiomyopathy","author":"Rigato","year":"2015","journal-title":"Cardiovasc Drugs Ther."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.052","article-title":"Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry","author":"Marcus","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.86.1.29","article-title":"Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia","author":"Wichter","year":"1992","journal-title":"Circulation."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017944","article-title":"Treatment of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: an international task force consensus statement","author":"Corrado","year":"2015","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/jce.13861","article-title":"Recurrent ventricular tachycardia after catheter ablation in arrhythmogenic right ventricular cardiomyopathy: scar progression or ineffective ablation?","author":"Bala","year":"2019","journal-title":"J Cardiovasc Electrophysiol."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz103","article-title":"A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy","author":"Cadrin-Tourigny","year":"2019","journal-title":"Eur Heart J."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2018.01.031","article-title":"Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis","author":"Bosman","year":"2018","journal-title":"Heart Rhythm."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2016.5034","article-title":"Evaluation of structural progression in arrhythmogenic right ventricular dysplasia\/cardiomyopathy","author":"Mast","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.927988","article-title":"Enalapril in infants with single ventricle: results of a multicenter randomized trial","author":"Hsu","year":"2010","journal-title":"Circulation."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00412-4","article-title":"Angiotensin-converting enzyme (ACE) inhibitors revert abnormal right ventricular filling in patients with restrictive left ventricular disease","author":"Henein","year":"1998","journal-title":"J Am Coll Cardiol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/hc3401.093149","article-title":"Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway","author":"Rouleau","year":"2001","journal-title":"Circulation."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(92)90529-V","article-title":"Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial","author":"Fonarow","year":"1992","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq025","article-title":"Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: proposed modification of the task force criteria","author":"Marcus","year":"2010","journal-title":"Eur Heart J."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.06.043","article-title":"Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia\/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention","author":"Bhonsale","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.77.6.1266","article-title":"Monophasic action potentials at discontinuation of cardiopulmonary bypass: evidence for contraction-excitation feedback in man","author":"Taggart","year":"1988","journal-title":"Circulation."},{"key":"B21","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"Yusuf","year":"1992","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.10.2573","article-title":"Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy","author":"Greenberg","year":"1995","journal-title":"Circulation."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22884","article-title":"Blockade of the renin-angiotensin-aldosterone system in patients with arrhythmogenic right ventricular dysplasia: A double-blind, multicenter, prospective, randomized, genotype-driven study (BRAVE study)","author":"Morel","year":"2018","journal-title":"Clin Cardiol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610173351604","article-title":"Evidence of apoptosis in arrhythmogenic right ventricular dysplasia","author":"Mallat","year":"1996","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr392","article-title":"Restrictive loss of plakoglobin in cardiomyocytes leads to arrhythmogenic cardiomyopathy","author":"Li","year":"2011","journal-title":"Hum Mol Genet."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201507018","article-title":"Plakophilin-2 loss promotes TGF-\u03b21\/p38 MAPK-dependent fibrotic gene expression in cardiomyocytes","author":"Dubash","year":"2016","journal-title":"J Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2003.10.055","article-title":"Perp is a mediator of p53-dependent apoptosis in diverse cell types","author":"Ihrie","year":"2003","journal-title":"Curr Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1038\/s41598-018-21600-w","article-title":"Angiotensin-converting enzyme inhibitor reduces scar formation by inhibiting both canonical and noncanonical TGF-beta1 pathways","volume":"8","author":"Fang","year":"2018","journal-title":"Sci Rep."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000036035.41122.99","article-title":"Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction","author":"Agata","year":"2002","journal-title":"Hypertension."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000237862.94083.45","article-title":"Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat","author":"Ocaranza","year":"2006","journal-title":"Hypertension."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.32.3.496","article-title":"Converting enzyme determines plasma clearance of angiotensin-(1-7)","author":"Yamada","year":"1998","journal-title":"Hypertension."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034755","article-title":"Is sacubitril\/valsartan (Also) an antiarrhythmic drug?","author":"Sarrias","year":"2018","journal-title":"Circulation."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.1.31","article-title":"Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias","author":"Makkar","year":"2009","journal-title":"Pharmacotherapy."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e31815addd9","article-title":"Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects","author":"Katragadda","year":"2010","journal-title":"Am J Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/j.ejim.2017.07.016","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability","volume":"44","author":"Correale","year":"2017","journal-title":"Eur J Intern Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92697-4","article-title":"Arrhythmia in heart failure: role of mechanically induced changes in electrophysiology","author":"Dean","year":"1989","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/28.2.201","article-title":"Fosinoprilate prolongs the action potential: reduction of iK and enhancement of the L-type calcium current in guinea pig ventricular myocytes","author":"R\u00e4cke","year":"1994","journal-title":"Cardiovasc Res."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.769138\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T04:53:31Z","timestamp":1636692811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.769138\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":37,"alternative-id":["10.3389\/fcvm.2021.769138"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.769138","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"article-number":"769138"}}